Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Archive Search

1 results
12:40 PM, Feb 03, 2017  |  BC Week In Review | Clinical News  |  Regulatory

Zioxtenzo regulatory update

EMA's CHMP said Novartis withdrew its MAA for Zioxtenzo, its biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Pegfilgrastim is a pegylated G-CSF. Last year, FDA issued a complete response...